



# New Hampshire Fee-For-Service Medicaid Pharmacy Program

**TO:** New Hampshire Medicaid Providers

**FROM:** New Hampshire Department of Health and Human Services/Prime Therapeutics

**DATE:** December 1, 2025

**SUBJECT:** NH Fee-for-Service (FFS) Medicaid Clinical Prior Authorization (PA)

Updates/Preferred Drug List (PDL)Web Portal Information/E-mail Notifications

This provides notice of changes being made to the New Hampshire Medicaid FFS Pharmacy program effective January 1, 2026.

The following clinical Prior Authorization updates have been made.

## **CLINICAL PRIOR AUTHORIZATION REVISIONS:**

Asthma/Allergy Immunomodulator	Lenmeldy™ (atidarsagene autotemcel)
Calcitonin Gene-Related Peptide (CGRP) Inhibitor	Long-Acting Opioid Analgesic
Cholestatic Pruritis	Proprotein Convertase Subtilisin/Kexin Type 9
	(PCSK9)
CNS Stimulant and ADHD/ADD Medications	Short-Acting Fentanyl
Codeine for Pediatric Use	Skin Disorders
Drugs for Bowel Disorders/GI Motility, Chronic	Skysona™ (elivaldogene autotemcel)
Duchenne Muscular Dystrophy Agents	Spinal Muscular Atrophy (SMA)
Dupixent® (dupilumab)	Systemic Immunomodulators
Epidermolysis Bullosa	Weight Management
Hematopoietic Agent	Zurzuvae™ (zuranolone)
Human Growth Hormones	Zynteglo™ (betibeglogene autotemcel)

#### **RETIRED CLINICAL PRIOR AUTHORIZATION CRITERIA:**

1. Rezdiffra®

## **NEW CLINICAL PRIOR AUTHORIZATION CRITERIA ADDITIONS:**

- 1. Crenessity™ (crinecerfont)
- 2. Encelto™ (revakinagene taroretcel-lwey)
- 3. Imcivree™ (setmelanotide)
- 4. MACE Wegovy®
- 5. MASH Criteria
- 6. OSA Zepbound™
- 7. Tryngolza™ (olezarsen)
- 8. Vykat™ XR (diazoxide choline)





#### PREFERRED DRUG LIST CHANGES:

The following additions of **preferred agents** have been made to the therapeutic drug classes on the NH FFS Medicaid PDL.

- Cardiovascular Angiotensin II Receptor Blockers and Combinations: sacubitril/valsartan
- Gastrointestinal Ulcerative Colitis: mesalamine suppositories
- Miscellaneous Smoking Cessation: varenicline

The following medications have been added to the NH FFS Medicaid PDL as **non-preferred agents**. Patients currently taking a non-preferred drug should be considered for a transition to a preferred drug. Non-preferred drugs will require **prior authorization**.

- Behavioral Health Anticonvulsants Second Generation: Gabarone™
- Behavioral Health Anxiolytics: Bucapsol™
- Behavioral Health Alzheimer's Agents: Zunveyl
- Cardiovascular Angiotensin II Receptor Blockers and Combinations: Arbli™, Entresto®
- Central Nervous System Antimigraine, Triptans: Symbravo®
- Endocrinology Dipeptidyl Peptidase-4 (DPP4) Inhibitors and Combinations:
  Brynovin™
- Endocrinology Insulins Rapid Acting: Merilog™
- Gastrointestinal Ulcerative Colitis: Canasa®
- Genitourinary/Renal Electrolytes: Calphron®
- Hematologic Colony Stimulating Factors: Nypozi™, Ryzneuta®
- Immunologic Systemic Immunomodulators: Imuldosa™, Legselvi™
- Ophthalmics Anti-inflammatory/Immunomodulators: Tryptyr®
- Topical Topical Agents for Psoriasis: Zoryve® foam

The following therapeutic drug class will be removed from the NH FFS Medicaid PDL on January 1, 2026.

• Endocrinology – Weight Management

As communicated previously, New Hampshire Medicaid will no longer cover GLP-1 medications when prescribed solely for weight loss. These medications will continue to be covered when prescribed for other chronic health conditions.

The most recent version of the NH FFS Medicaid PDL and Prior Authorization fax forms are available online and may be obtained by visiting the Prime Therapeutics website at: <a href="mailto:nh.primetherapeutics.com">nh.primetherapeutics.com</a>.

If you have questions regarding the content of this notice, please contact the Prime Therapeutics Clinical Manager at (612) 318-5936. In addition, the Prime Therapeutics Clinical Call Center is





# New Hampshire Medicaid – CMS Participating Labelers

For a drug to be covered by New Hampshire Medicaid, the manufacturer of the drug must participate in the Medicaid Drug Rebate Program (MDRP). More information on the specifics of this program can be found at <a href="https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html">https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html</a> You can access quarterly updates to active at <a href="https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html">https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html</a> You can access quarterly updates to active at <a href="https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html">https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html</a>

## **Emergency Drug Coverage**

Pharmacies are reminded that federal statute requires Medicaid programs (Fee-for-Service and managed care) provide payment for dispensing of at least a 72-hour supply for any drugs requiring prior authorizations if prior authorization cannot be obtained outside of Medicaid business hours. (Section 1927 of the Social Security Act. Codified as Section 1396r-8 of Title 42.(d)(5)(B))

Pharmacies must request payment for the 72-hour supply from the client's prescription plan, either Fee-For-Service or the appropriate Medicaid MCO.

## **Pharmacy Co-payment**

Medicaid providers are not permitted to require Medicaid recipients to pay copayments as a condition for receiving services. However, the consequences for a recipient who does not pay the copayment is that the provider:

- (a) may request the copayment each time a recipient needs an item or service;
- (b) may ask a recipient for outstanding copayments the next time the recipient comes in for an item or service, or
- (c) may send the recipient bills.

## **Early Refill Override**

ProDUR edits indicating Overuse/Early Refill can only be overridden by contacting the Prime Therapeutics Technical Support Center at 1-866-664-4511 and requesting an override. A justification for the early refill request will be requested to assist with record keeping and to assist with fraud and abuse prevention. You can access this information in the Pharmacy Manual at <a href="https://nh.primetherapeutics.com">nh.primetherapeutics.com</a>.

#### **New Hampshire Medicaid Web Portal**

Prescribers and pharmacies have access to NH FFS Medicaid drug specific data including coverage, prior authorization required, preferred drugs, quantity limits, dose optimization and the pharmacy provider manual. You can access this information at nh.primetherapeutics.com.

#### **Email notifications**

If you wish to receive e-mail notifications regarding New Hampshire FFS Medicaid Pharmacy Program changes, please enter your e-mail address at <a href="https://nh.primetherapeutics.com">nh.primetherapeutics.com</a> under the Resources, Contact Us tab.